Application of miR2911 in the preparation of drugs against porcine reproductive and respiratory syndrome virus

By combining miR2911 with the targets of pig breeding and respiratory syndrome virus, drugs for anti-pig breeding and respiratory syndrome virus were developed, which solved the problem of the lack of effective drugs for existing treatment methods and achieved significant inhibition of the virus The effects of replication and titer provide new methods for the treatment of pig reproductive and respiratory syndrome virus.

CN117919267BActive Publication Date: 2024-12-03SHIHEZI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410100321.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-24
Publication Date
2024-12-03
Estimated Expiration
2044-01-24

AI Technical Summary

Technical Problem

The existing treatment methods for anti-pig reproductive and respiratory syndrome virus lack effective drugs, and the application of honeysuckle-derived miR2911 in this field has not been explored.

Method used

By combining miR2911 with targets of pig reproductive and respiratory syndrome virus to significantly inhibit the replication and expression of the virus, drugs for the preparation of anti-pig reproductive and respiratory syndrome viruses, including combinations of miR2911 overexpression and vectors were developed. Use targeted specific genes that inhibit viruses such as orf1a and orf7, reducing viral titer and N protein expression.

Benefits of technology

miR2911 significantly inhibited the replication and titer of pig reproductive and respiratory syndrome virus, proving that it has strong antiviral activity, and provides a new path for the treatment of pig reproductive and respiratory syndrome virus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117919267B_ABST
    Figure CN117919267B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biotechnology, and specifically relates to the use of miR2911 in the preparation of drugs against porcine reproductive and respiratory syndrome virus, wherein the sequence of miR2911 is shown in SEQ ID NO: 1. The present invention also discloses a porcine reproductive and respiratory syndrome virus inhibitor, wherein the inhibitor contains miR2911, and the present invention verifies at the cellular level that miR2911 can significantly inhibit luciferase activity by binding to porcine reproductive and respiratory syndrome virus targets; and through experiments of miR2911 overexpression and porcine reproductive and respiratory syndrome virus infection, it is confirmed that miR2911 has strong antiviral activity, which provides a new path for the research and development of antiviral drugs for porcine reproductive and respiratory syndrome virus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and particularly relates to application of miR2911 in preparing drugs for resisting porcine reproductive and respiratory syndrome virus. Background Art

[0002] miRNA (microRNA) is a type of non-coding RNA with a length of about 18 to 25 nt and is highly conserved. Generally, the maturation of miRNA goes through four stages: pri-miRNA is transcribed in the nucleus, pre-miRNA is cleaved by RNaseIII-Drosha enzyme, and pre-miRNA is transported out of the nucleus and enters the cytoplasm to mature. When the RISC containing the miRNA guide chain is not completely complementary to the 3'UTR of the target mRNA, it blocks the translation of the target gene and inhibits the expression of the target gene; when it is completely complementary to the target mRNA, the target mRNA is cut and degraded by the AGO2 protein. The sequence and structure of miRNA are diverse, and they play an important role in biological regulation and protein synthesis, including the proliferation and apoptosis of diseased cells, cancer treatment, and viral infection.

[0003] Honeysuckle is sweet and cold in nature, clears away heat and detoxifies, and reduces inflammation and swelling. It is an important traditional Chinese medicine and is widely used to treat influenza virus and other infections. In 2015, Zhen Zhou found that the abundance of miR2911 in mice that were fed honeysuckle soup was high. MiR2911 can target a variety of influenza A viruses (IAVs). Chemically synthesized miR2911 not only significantly inhibits the expression of PB2 and SN1 proteins of H1N1, but also reduces the mortality rate of H5N1-infected mice. Researchers have also found that miR2911 can effectively inhibit the replication of SARS-CoV-2, and miR2911 has multiple inhibitory targets in the SARS-CoV-2 gene region. MiR2911 is stable in nature, resistant to high temperature boiling, and enters the animal body through the digestive system to exert its biological functions.

[0004] Porcine reproductive and respiratory syndrome virus (PRRSV) is an enveloped, single-stranded, positive-sense RNA virus of the genus Arterivirus ( Arteriviridae ), mainly infects alveolar macrophages, and clinically often induces acute respiratory diseases in piglets and reproductive disorders in sows. PRRSV belongs to the family Arteriviridae. Betaarterivirus suid The PRRSV genome is about 15 kb long and contains a 5'UTR, at least 10 open reading frames (ORFs), a 5'-UTR and a 3' poly(A) tail. PRRSV has the following two genotypes: PRRSV-1 of European origin ( Betaarterivirus suid 1 ) and PRRSV-2 of North American origin ( Betaarterivirus suid 2). Porcine reproductive and respiratory syndrome (PRRS) was first discovered in the United States in 1987; after 2012, recombinant strains of new GM2 and NADC30-like appeared; after 2015, NADC30 like viruses began to spread; the emergence of NADC30-like strains may be due to the recombination of North American NADC30 strains and HP-PRRSV strains. Although not as highly pathogenic as HP-PRRSV, NADC30-like strains have a high recombination rate with other virus strains, resulting in changes in virulence. In addition, NADC30-like strains may break out in vaccinated pigs. Studies have shown that recombination caused by co-infection of different strains or genotypes makes the epidemiology of PRRSV strains more complex and diverse. Since the outbreak of ASF in 2018, the prevention and control of major viral infectious diseases in pigs has become more severe. The old diseases have not been eliminated, and the continuous increase of new diseases is the main problem facing the pig industry. Viral infectious diseases often require immune vaccines for prevention and control, and there are no specific therapeutic drugs. After searching, no application of honeysuckle-derived miR2911 in anti-porcine reproductive and respiratory syndrome virus was found. Summary of the invention

[0005] The present invention provides a new use of miR2911, specifically relates to the use of miR2911 in the preparation of drugs against porcine reproductive and respiratory syndrome virus. The present invention verifies that miR2911 can significantly inhibit luciferase activity by binding to PRRSV target sites; through miR2911 overexpression and PRRSV infection experiments, it is confirmed that miR2911 has strong antiviral activity.

[0006] In order to solve the above technical problems, the present invention adopts the following technical solutions.

[0007] The first aspect of the present invention provides the use of honeysuckle-derived miR2911 in the preparation of drugs against porcine reproductive and respiratory syndrome virus.

[0008] In some embodiments of the present invention, the sequence of miR2911 is shown in SEQ ID NO:1.

[0009] In some embodiments of the present invention, the drug is used for the replication of porcine reproductive and respiratory syndrome virus.

[0010] In some embodiments of the present invention, the drug is used to reduce the titer of porcine reproductive and respiratory syndrome virus.

[0011] In some embodiments of the present invention, the drug targets and inhibits porcine reproductive and respiratory syndrome virus orf1a Gene.

[0012] In some embodiments of the present invention, the drug is used to target and inhibit porcine reproductive and respiratory syndrome virus. orf7 Gene.

[0013] In some embodiments of the present invention, the drug is used to reduce the expression level of porcine reproductive and respiratory syndrome virus N protein.

[0014] The second aspect of the present invention provides an inhibitor of porcine reproductive and respiratory syndrome virus, wherein the inhibitor comprises miR2911; preferably, the inhibitor has miR2911 as the only effective active ingredient.

[0015] The third aspect of the present invention provides a pharmaceutical composition, which comprises the inhibitor and a pharmaceutically acceptable carrier, virus or excipient.

[0016] In some embodiments of the present invention, the carrier is selected from one or more of cholesterol, nanoparticles and liposomes.

[0017] In some embodiments of the present invention, the virus is selected from one or more of an adenoviral vector, a lentiviral vector, and a retroviral vector.

[0018] In some embodiments of the present invention, pharmaceutically acceptable excipients broadly refer to any component other than the active therapeutic ingredient. Excipients can be inert substances, inactive substances and / or non-pharmaceutically active substances. Excipients can be used for various purposes, such as as carriers, vehicles, diluents, tablet adjuvants and / or to improve the administration and / or absorption of active substances.

[0019] In some embodiments of the present invention, the excipient is selected from one or more of solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids and release retardants.

[0020] In some embodiments of the present invention, the filler is selected from starch, sucrose, lactose or microcrystalline cellulose; the binder is selected from cellulose derivatives, alginate, gelatin or polyvinyl pyrrolidone; the wetting agent is selected from water, glycerol, ethanol, methylcellulose, sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose or hydroxypropyl methylcellulose; the disintegrant is selected from sodium carboxymethyl starch, hydroxypropyl cellulose, cross-linked carboxymethyl cellulose, agar, calcium carbonate or sodium bicarbonate; the absorption promoter is a quaternary ammonium compound; the surfactant is selected from cetyl alcohol or sodium lauryl sulfate; the adsorption carrier is selected from kaolin or bentonite; the lubricant is selected from talc, calcium and magnesium stearate, micropowder silica gel or polyethylene glycol; the flavoring agent is selected from sucrose, monosyrup, aromatic syrup, glycerol, sorbitol or mannitol.

[0021] Compared with the prior art, the present invention has the following beneficial effects: the present invention discloses for the first time the use of honeysuckle-derived miR2911 in the preparation of drugs against porcine reproductive and respiratory syndrome virus, providing a new use for miR2911.

[0022] In the present invention, miRNA is used to target the PRRSV gene region, and it is preliminarily proved that the predicted miR2911 targeting region has a strong effect. Through the antiviral analysis of miR2911, it was found that PRRSV orf7 The gene expression level decreased significantly, and the virus titer and viral N protein also decreased significantly, indicating that miR2911 is effective in antiviral treatment. The PRRSV gene was subcloned into the XbaⅠ restriction site of pGL3-promoter through gene synthesis technology to obtain the pGL3-promoter-PRRSV plasmid, which verified at the cellular level that miR2911 can significantly inhibit luciferase activity by binding to the PRRSV target; further, miR2911 overexpression and PRRSV infection experiments confirmed that miR2911 has strong antiviral activity, providing a new path for the development of PRRSV antiviral drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the result of miR2911 targeting PRRSV gene analysis; where “:” indicates base mismatch.

[0024] Figure 2 Evolutionary tree analysis of the virus region targeted by miR2911, targeting the multi-region sequence evolutionary tree of the PRRSV gene.

[0025] Figure 3 This is a graph showing the inhibitory effect of miR2911 on the luciferase activity of pGL3-promoter-PRRSV.

[0026] Figure 4Effect of miR2911 on PRRSV orf7 Relative expression results of gene mRNA.

[0027] Figure 5 This is a graph showing the virus titer results.

[0028] Figure 6 The figure shows the expression level of viral N protein. DETAILED DESCRIPTION

[0029] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.

[0030] 1. Experimental Materials

[0031] DMEM medium (HyClone), fetal bovine serum (Gibco™), PBS (HyClone), dual luciferase activity assay kit (Novagen Biotech), Escherichia coli DH5α (Sangon Biotech), pRL-TK plasmid (Sangon Biotech), pGL3-promoter plasmid (Sangon Biotech), and pGL3-promoter-PRRSV plasmid were provided by Sangon Biotech (Zhengzhou). MARC-145 cells and HEK293T cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) and antibiotics (100 U / mL penicillin and 100 U / mL streptomycin).

[0032] The PRRSV (XJzx1-2015) used in the present invention is disclosed in the article High-frequency mutation and recombination are responsible for the emergence of novel porcine reproductive and respiratory syndrome virus in northwest China. Rch Virol. 2019 Nov; 164 (11): 2725-2733. doi: 10.1007 / s00705-019-04373-z. Epub 2019 Aug 29. PMID: 31468140.

[0033] Example 1 Analysis of the inhibitory effect of honeysuckle miR2911 targeting PRRSV gene

[0034] 1. Obtaining the sequence of honeysuckle miR2911

[0035] The mature sequence of honeysuckle-derived miR2911 was downloaded from the miRbase database (http: / / www.mirbase.org / index.shtml), 5′-GGCCGGGGGACGGACUGGGA-3′, with the sequence number being SEQ ID NO: 1.

[0036] 2. Download the complete gene sequence of PRRSV

[0037] Enter the NCBI (https: / / www.ncbi.nlm.nih.gov / ) database, search for the full genome sequence of PRRSV, and choose to download the full genome sequence of the current prevalent strain in my country.

[0038] 3. Prediction of miRNAs targeting PRRSV gene regions

[0039] In the Windows environment, open CMD (command prompt) and enter the CMD code to run the miRanda software. Start the miRanda software and analyze the targeted regions of miR2911 in the PRRSV full gene sequence.

[0040] 4. Construction of targeted regional evolutionary tree

[0041] miR2911 targeted PRRSV gene region comparison, downloaded PRRSV sequences of different epidemic strains, and constructed an evolutionary tree using the neighbor method.

[0042] 5. Targeted area verification

[0043] HEK293T cells were co-transfected with miR2911 homologs and pGL3-promoter-PRRSV plasmid, and miRNAs negative control was co-transfected with pGL3-promoter-PRRSV plasmid as a control, and the ratio of pGL3-promoter-PRRSV plasmid to pRL-TK plasmid (Sangon Biotech) was 50 to 1. After 24 h of transfection, the analysis was performed using the instructions of the Novizan Dual Luciferase Reporter Gene Assay Kit.

[0044] The pGL3-promoter-PRRSV plasmid is obtained by subcloning the PRRSV gene into the XbaⅠ restriction site of pGL3-promoter through gene synthesis technology. The PRRSV gene sequence is 5'-TCTCAGTGCACGGTCCCTCCTTCTTTGAAACTGTCCCCGGGGACGCCAGTATGGCTGCCTCCCGGCTACCCAACACGTCACCATTGGCCGCCTAGTAGTGTTATCCCGGCCTCCCTTCCGTTCCCCAGTC-3', and the sequence number is SEQ ID NO:2.

[0045] 6. Antiviral analysis of miR2911

[0046] MARC-145 cells were inoculated in 24-well plates and cultured overnight. Then, miR2911 was transfected. miRNA NC was used as a control. 12 h after transfection, the cells were infected with 0.1 MOI of PRRSV (XJzx1-2015). 24 h after infection, the virus was measured. orf7 Gene expression and virus titer.

[0047] (1) Viruses orf7 Gene expression was measured as follows:

[0048] MARC-145 cells were inoculated into 24-well plates and cultured overnight. Then, they were transfected with miR2911 and miRNA NC as a control. 12 h after transfection, the cells were infected with 0.1 MOI of PRRSV. 24 h after infection, the cells were harvested and lysed with trizol to determine the PRRSV orf7 Gene expression level, the specific steps are as follows:

[0049] Total RNA extraction: cells were lysed with 1 mL TRIzol® reagent (Takara), 200 μL chloroform was added and shaken vigorously for 30 seconds (Second, s), allowed to stand at room temperature for 5 minutes, centrifuged at 4°C 12000g for 10 minutes, 500 μL supernatant was aspirated and transferred to a new EP tube, 500 μL isopropanol was added and mixed by inversion, allowed to stand at room temperature for 15 minutes, centrifuged at 4°C for 15 minutes, the supernatant was discarded and 1 mL 75% ethanol was added, centrifuged at 4°C for 6 minutes, the ethanol was dried upside down, total RNA was dissolved with 20 μL RNase-free water, and genomic DNA was removed using DNaseIRNase (TaKara). RNA quality was determined using ND-2000 (NanoDrop Technologies).

[0050] Reverse transcription: The extracted RNA was reverse transcribed into cDNA. The reverse transcription system and procedure were as follows: Oligo-dT (10 μM), Super Pure dNTPs (20 mM) 0.5 μL, Tota RNA 1 μg, RNase free H2O 14.5 μL; incubated at 65°C for 5 min on a PCR instrument, and then incubated on ice for 2 min. The following was added to the above reaction mixture: 5×ScriptⅡRTaseBuffer 4uL, RNasin (40 U / μL) 0.5μL, ScriptⅡRTase (200 U / μL) 1μL, total volume 20μL; incubated at 42°C for 70 min on a PCR instrument, heated at 85°C for 10 min (or heated at 70°C for 15 min) to terminate the reaction, and placed on ice for subsequent experiments.

[0051] Using ACTIN as the internal reference gene and PRRSV orf7 For the target gene, synthesize primers (as shown in Table 1). Amplify using cDNA as template orf7 Genes were analyzed by RT-qPCR according to the instructions of SYBR® Premix (Yisheng Biotechnology Co., Ltd.). The reaction system was 20 μL: 10 μL SYBR, 2 μL cell cDNA, 0.4 μL upstream and downstream primers, 0.4 μL ROX, 6.8 μL ddH2O; the reaction program was: 95℃ pre-denaturation for 5 min; 95℃ 10 s, 60℃ 10 s, 72℃ 30 s, 40 cycles. Three replicates were set for each group of samples, and the obtained data were analyzed by 2-ΔΔCt calculation. GraphPad Prism5.0 was used to draw charts and perform differential analysis.

[0052] Table 1 Real-time fluorescence quantitative PCR primer information

[0053] Primers Sequence (5′-3′) serial number Prrsv--F ATCCAGACTGCCTTCAAT SEQ ID NO:3 Prrsv--R AACTCCACAGTGTAACTTATC SEQ ID NO:4 Monkey-actin-F CGGGAAATCGTGCGTGAC SEQ ID NO:5 Monkey-actin-R ATGCCCAGGAAGGAAGGTTG SEQ ID NO:6

[0054] (2) Virus titer determination was performed using the following method:

[0055] Titer unit: TCID 50 / mL refers to the amount of virus required to cause half of the cells to be cytopathic or dead (cytopathic effect, CPE) in the wells of the culture plate or test tube, which means the number of dilutions required for the virus contained in each mL of sample to cause 50% cell infection.

[0056] (1) Cell preparation

[0057] Digest and count the MARC-145 cells that are growing well, dilute to 1×100,000 / mL, add to a 96-well plate, 100 μL / well, prepare 6 dilutions for each virus, 10 wells for each dilution, and culture in a 37°C, 5% carbon dioxide incubator.

[0058] (2) Add virus

[0059] Make 10-fold gradient dilutions in EP tubes, and make 6 dilutions in succession. The dilution method is as follows: prepare 6 1.5 mL EP tubes for each virus, add 900 μL of culture medium to each tube, add 100 μL of virus stock solution to the first tube, mix well, then pipette 100 μL and add to the second tube to mix well. And so on, make 6 dilutions (0.1-0.000001).

[0060] Aspirate the original culture medium in the 96-well plate, add the diluted virus solution, and mark it.

[0061] (3) Adding culture medium

[0062] Add 100 μL of complete culture medium to each well to facilitate cell growth.

[0063] (4) Observe the results and calculate the titer

[0064] After 3-4 days of culture, the cytopathic effect was observed under an inverted microscope, and the virus titer was calculated using the Reed-Muench method and expressed as a cell half-lethal dose (TCID 50 / mL); the calculation formula is as follows:

[0065] Distance ratio = (percentage of lesions above 50% - 50%) / (percentage of lesions above 50% - percentage of lesions below 50%)

[0066] lgTCID50=distance ratio×difference between logarithms of dilution+logarithm of dilution with higher than 50% lesion rate.

[0067] 7. Experimental results

[0068] (1) Analysis of miR2911-targeted PRRSV gene regions

[0069] like Figure 1 As shown in Figure 2, miR2911 can target PRRSV as predicted by miRanda software. orf1a Gene (four regions of Nsp2 and two regions of Nsp1). The results showed that miR2911 could well target the 2459-2477 region of PRRSV Nsp2, with a score of 106 points and a free energy of -30.959999 kCal / Mol.

[0070] (2) Phylogenetic tree analysis of the PRRSV gene region sequence targeted by miR2911

[0071] The sequences of the PRRSV gene regions targeted by miR2911 were downloaded from the NCBI database, and multiple regions were linked in sequence. The evolutionary tree of the virus gene regions targeted by miR2911 was constructed using the neighbor method in MEGA 7.0 software. Figure 2 As shown, the homology of the PRRSV gene region targeted by miR2911 is over 80%, and only 2-4 base mutations exist in different strains.

[0072] (3) Analysis of the inhibitory effect of miR2911 targeting PRRSV gene

[0073] like Figure 3 As shown in the figure, using the dual luciferase experiment, it was found that miR2911 can significantly inhibit luciferase activity by binding to the target on PRRSV. Compared with the NC group, the luciferase activity of the miR2911 group decreased by more than 2 times, which preliminarily proved that the predicted miR2911 targeting area has a strong effect.

[0074] (4) miR2911 significantly inhibits PRRSV replication

[0075] like Figure 4 , Figure 5 , Figure 6 As shown, overexpression of miR2911 in marc-145 cells significantly inhibited PRRSV. orf7 The gene expression level decreased significantly, and the viral titer and viral N protein also decreased significantly. The lower the viral titer, the weaker the viral replication ability and the weaker the infectivity. The decrease in viral titer also indicates that miR2911 antiviral treatment is effective.

[0076] The miRanda software was used to analyze the specific regions, scores, and free energy of the PRRSV gene targeted by miR2911, and further analyze the conservation of the viral regions targeted by miR2911, in order to provide reference for the treatment of swine viral infectious diseases. The study found that miR2911 can target two genes of PRRSV, one of which is Nsp2 There are 4 target regions on the gene, in PRRSV Nsp1 There are 2 targeted regions on the gene.

[0077] PRRSV will have mutant strains every 8-10 years, especially PRRSV Nsp2 Genes play an important role in mutation. Nsp2 Genes are missing and mutated in different strains. Sequence comparison analysis revealed that only a few bases were mutated in the target sites of different PRRSV strains. Nsp2 The target on the gene avoids the missing region. Therefore, honeysuckle-derived miR2911 has the potential to inhibit the replication of the current PRRSV epidemic strains. For the targeted region of miR2911 on PRRSV, although there are mutations in 2-3 sites in different strains, they still show high homology. miR2911 can inhibit viral replication by targeting the PRRSV nsp2 region.

[0078] The target of miR2911 in the PRRSV gene is relatively conservative, and the target homology of isolates from different periods and regions is high. Therefore, honeysuckle-derived miR2911 has the potential to inhibit the replication of the current PRRSV epidemic strains. The PRRSV gene was subcloned into the XbaⅠ restriction site of pGL3-promoter through gene synthesis technology to obtain the pGL3-promoter-PRRSV plasmid, and it was verified at the cellular level that miR2911 can significantly inhibit luciferase activity by binding to the PRRSV target; further, miR2911 overexpression and PRRSV infection experiments were performed to confirm that miR2911 has strong antiviral activity, providing a new path for the development of PRRSV antiviral drugs.

[0079] Of course, the above description is not a limitation of the present invention, and the present invention is not limited to the above examples. Any changes, modifications, additions or substitutions made by ordinary technicians in this technical field within the essential scope of the present invention should fall within the protection scope of the present invention.

[0080] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0081] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. Use of honeysuckle-derived miR2911 in the preparation of drugs against porcine reproductive and respiratory syndrome virus, the sequence of the miR2911 being shown in SEQ ID NO:

1.

2. The use according to claim 1, characterized in that The drug is used for inhibiting the replication of porcine reproductive and respiratory syndrome virus.

3. The use according to claim 1, characterized in that The drug is used for reducing the titer of porcine reproductive and respiratory syndrome virus.

4. The use according to claim 1, characterized in that The drug targets and inhibits the orf1a gene of porcine reproductive and respiratory syndrome virus.

5. The use according to claim 1, characterized in that The drug is used for inhibiting the expression of orf7 gene of porcine reproductive and respiratory syndrome virus.

6. The use according to claim 1, characterized in that The drug is used for reducing the expression level of the N protein of porcine reproductive and respiratory syndrome virus.